Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gianpaolo Reboldi

Showing results (1-10 of 264) with videos related to

Pageof 27
Sort By:
Giornale Italiano Di Cardiologia (2006)|September 19, 2009
[Drug therapy of type 2 diabetes and cardiovascular prevention: potentials for liraglutide]Gianpaolo Reboldi
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|June 20, 2015
Enhancing the Benefit of Bivalirudin in Percutaneous Coronary Intervention: Is High Risk of Bleeding the Key?Fabio Angeli, Gianpaolo Reboldi
Lancet (London, England)|August 19, 2014
Risk and decision making in patients with hypertensionPaolo Verdecchia, Gianpaolo Reboldi
Hypertension (Dallas, Tex. : 1979)|May 23, 2012
"From apennines to andes:" does body mass index affect the relationship between age and blood pressure?Fabio Angeli, Gianpaolo Reboldi, Paolo Verdecchia
European Journal of Internal Medicine|September 25, 2020
The 2020 International Society of Hypertension global hypertension practice guidelines - key messages and clinical considerationsPaolo Verdecchia, Gianpaolo Reboldi, Fabio Angeli
Hypertension (Dallas, Tex. : 1979)|July 20, 2023
It Is Time to Reconsider the Blood Pressure Targets in Patients With Type 2 Diabetes?Paolo Verdecchia, Gianpaolo Reboldi, Fabio Angeli
American Journal of Hypertension|February 11, 2021
The Link Between Inflammation and Hypertension: Unmasking MediatorsFabio Angeli, Gianpaolo Reboldi, Paolo Verdecchia
Journal of Hypertension|May 7, 2020
Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and coronavirusPaolo Verdecchia, Fabio Angeli, Gianpaolo Reboldi
Expert Opinion on Drug Safety|May 26, 2011
Good news for β-blockers in perioperative medicineFabio Angeli, Gianpaolo Reboldi, Paolo Verdecchia
Expert Opinion on Pharmacotherapy|February 18, 2011
Modern treatment of patients at risk: still a HOPE for ACE inhibitors?Fabio Angeli, Gianpaolo Reboldi, Paolo Verdecchia
Pageof 27

Showing results (1-10 of 264) with videos related to

Sort By:
Pageof 27
Giornale Italiano Di Cardiologia (2006)|September 19, 2009
[Drug therapy of type 2 diabetes and cardiovascular prevention: potentials for liraglutide]Gianpaolo Reboldi
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|June 20, 2015
Enhancing the Benefit of Bivalirudin in Percutaneous Coronary Intervention: Is High Risk of Bleeding the Key?Fabio Angeli, Gianpaolo Reboldi
Lancet (London, England)|August 19, 2014
Risk and decision making in patients with hypertensionPaolo Verdecchia, Gianpaolo Reboldi
Hypertension (Dallas, Tex. : 1979)|May 23, 2012
"From apennines to andes:" does body mass index affect the relationship between age and blood pressure?Fabio Angeli, Gianpaolo Reboldi, Paolo Verdecchia
European Journal of Internal Medicine|September 25, 2020
The 2020 International Society of Hypertension global hypertension practice guidelines - key messages and clinical considerationsPaolo Verdecchia, Gianpaolo Reboldi, Fabio Angeli
Hypertension (Dallas, Tex. : 1979)|July 20, 2023
It Is Time to Reconsider the Blood Pressure Targets in Patients With Type 2 Diabetes?Paolo Verdecchia, Gianpaolo Reboldi, Fabio Angeli
American Journal of Hypertension|February 11, 2021
The Link Between Inflammation and Hypertension: Unmasking MediatorsFabio Angeli, Gianpaolo Reboldi, Paolo Verdecchia
Journal of Hypertension|May 7, 2020
Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and coronavirusPaolo Verdecchia, Fabio Angeli, Gianpaolo Reboldi
Expert Opinion on Drug Safety|May 26, 2011
Good news for β-blockers in perioperative medicineFabio Angeli, Gianpaolo Reboldi, Paolo Verdecchia
Expert Opinion on Pharmacotherapy|February 18, 2011
Modern treatment of patients at risk: still a HOPE for ACE inhibitors?Fabio Angeli, Gianpaolo Reboldi, Paolo Verdecchia
Pageof 27